GCP
RAPP

GSA Capital Partners’s Rapport Therapeutics RAPP Stock Holding History

GSA Capital Partners’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Sell
9,928
-2,805
-22% -$78.9K 0.02% 1230
2025
Q4 		$386K Buy
+12,733
New +$352K 0.03% 997

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

GSA Capital Partners's RAPP Position: Q1 2026 in Review

GSA Capital Partners reduced its Rapport Therapeutics (RAPP) stake by 22% in Q1 2026, selling an estimated $78.9K and leaving 9,928 shares worth $311K. The position accounts for 0.02% of the portfolio, ranked #1230.

GSA Capital Partners first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. The position peaked at $386K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • GSA Capital Partners held 9,928 shares of Rapport Therapeutics worth $311K as of Q1 2026.
  • GSA Capital Partners sold 2,805 Rapport Therapeutics shares in Q1 2026, an estimated $78.9K.
  • Rapport Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1230 holding.
  • GSA Capital Partners first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GSA Capital Partners's Rapport Therapeutics position peaked at $386K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.